Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Iovance Biotherapeutics revenue
Iovance Biotherapeutics's revenue is $164.1 million.
What is Iovance Biotherapeutics's revenue?
- Iovance Biotherapeutics's revenue growth from 2023 to 2024 is 13,698.99%.
- Iovance Biotherapeutics has 319 employees, and the revenue per employee ratio is $514,326.
- Iovance Biotherapeutics's peak quarterly revenue was $73.7M in 2024(q4).
- Iovance Biotherapeutics peak revenue was $164.1M in 2024.
- Iovance Biotherapeutics annual revenue for 2024 was 164.1M, 13,698.99% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Iovance Biotherapeutics financial information
| CEO | Frederick G. Vogt |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 319 |
| Date Founded | 2007 |
| Headquarters | San Carlos, California |
| Number of Locations | 3 |
| Revenue | $164.1M |
| Net Income | -$395,893,000 |
| Gross Proft | $40.1M (2024) |
| Tax Rate | 0.0% |
| Total Assets | $663,982,000 |
| Ticker | IOVA |
Iovance Biotherapeutics jobs you might like
Iovance Biotherapeutics financing
Iovance Biotherapeutics received early financing of $23.0M on 2013-10-31.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $23M | 10/2013 |
| Post Ipo Equity | $64M | 02/2015 |
| Post Ipo Equity | $100M | 06/2016 |
| Post Ipo Equity | $172.5M | 01/2018 |
| Post Ipo Equity | $252.2M | 10/2018 |
| Post Ipo Equity | $603.7M | 05/2020 |
Iovance Biotherapeutics investors
| Investors | Security type |
|---|---|
| Quogue Capital | Post Ipo Equity |
| Frazier Healthcare Partners | Post Ipo Equity |
| Broadfin Capital | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
Iovance Biotherapeutics competitors
Iovance Biotherapeutics's top competitor, Gilead Sciences, earned an annual revenue of $28.8B.
Iovance Biotherapeutics's smallest competitor is Alzheon with revenue of $8.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | $85,008 | $2.0B | 900 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 735 |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Exelixis | $108,978 | $2.2B | 484 | 157 |
| Cubist Pharmaceuticals | $91,725 | $926.4M | 873 | - |
| Quidel | $71,489 | $1.7B | 1,500 | - |
| Ariad Pharmaceuticals | $94,078 | $118.8M | 380 | - |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 123 |
| Incyte | $103,592 | $4.2B | 1,600 | 38 |
| Alzheon | $71,794 | $8.0M | 5 | - |
Iovance Biotherapeutics revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Iovance Biotherapeutics highest paying jobs
Zippia gives an in-depth look into the details of Iovance Biotherapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Iovance Biotherapeutics. The employee data is based on information from people who have self-reported their past or current employments at Iovance Biotherapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Iovance Biotherapeutics. The data presented on this page does not represent the view of Iovance Biotherapeutics and its employees or that of Zippia.
Iovance Biotherapeutics may also be known as or be related to Iovance Biotherapeutics, Iovance Biotherapeutics Inc, Iovance Biotherapeutics Inc. and Iovance Biotherapeutics, Inc.